Xention Discovery to Present on the Role of Ion Channels in Pain
The Informa annual meeting on Ion Channel Targets is attended by many of the world’s leading scientists in ion channel research and brings together academic and industrial scientists to discuss the latest developments in the field. Dr Madge’s lecture will describe the current understanding of the role of ion channels in pain, the degree of validation of different ion channels as therapeutic targets and the tailoring of discovery programmes for the further development of modulators of specific ion channels.
‘We are delighted that the organisers have invited Dr Madge to speak at this prestigious event’, commented Tim Brears, Xention’s Chief Executive. ‘Xention has many years’ experience in ion channel drug discovery and development and, under Dr Madge’s leadership, our team has generated drug candidates with high potency and selectivity that we are progressing through development. Xention is recognised as having one of the best functional assay and chemistry capabilities in the industry for ion channel targets and this has led to partnerships with leading pharmaceutical companies and research consortia’.
Xention’s technologies are applicable to many medical fields where ion channels represent validated targets, including pain, cardiology, diseases of the CNS, immune disorders, respiratory disorders, oncology, anti-virals and ocular diseases. Xention’s internal programmes are focused on atrial fibrillation, for which the company is developing antagonists of the novel targets, IKur and IKACh, as potential breakthrough drugs in this area of high medical need.
For further information, please contact:
Tim Brears CEO Xention Limited 01223 493 900
Tristan Jervis De Facto Communications 020 7861 3838
About Xention:
Xention is a leader in the discovery and development of ion channel-modulating drugs. The Company is developing a pipeline of innovative products for the treatment of atrial fibrillation, an indication for which there is high unmet medical need, by targeting key ion channels. In addition, it has drug discovery collaborations with Ono Pharmaceutical Co Ltd and the Gr?nenthal Group. Xention is a member of the EUTRAF, EDICT and MAREX consortia focused on the identification of novel targets for atrial fibrillation, the structure and function of ion channels and the identification of new tools for the characterisation of ion channels respectively. The Company is the recipient of a prestigious drug discovery award from the Wellcome Trust and a grant under the Eurostars programme that supports market-oriented research in SMEs. Xention is a leader in the use of electrophysiology, ion channel chemoinformatics and medicinal chemistry and uses its innovative approach to discover and design potent and selective small-molecule drugs that target ion channels involved in a wide variety of diseases. For further information, please see http://www.xention.com.